Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT +1.50%64 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates SGHT with a GF Score™ of 64/100 and a GF Value™ of $4.68 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 445 Medical Devices & Instruments companies, Sight Sciences ranks worse than 224718.88% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sight Sciences's current 10-Year Share Buyback Ratio was 0.00%.
SGHT's 10-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -3.3 * Ranked among companies with meaningful 10-Year Share Buyback Ratio only.
Sight Sciences (NAS:SGHT) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Sight Sciences 10-Year Share Buyback Ratio Related Terms
SGHT vs CLPT, SENS, NPCE: 10-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Sight Sciences's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences 10-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Sight Sciences's 10-Year Share Buyback Ratio falls into.
Sight Sciences 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of 0.00 mean?
Sight Sciences (SGHT) has a 10-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #999999 out of 445 companies in the Medical Devices & Instruments industry.
Is Sight Sciences' 10-Year Share Buyback Ratio too high?
Sight Sciences' current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Sight Sciences ranks #999999 out of 445 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sight Sciences has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 10-Year Share Buyback Ratio compare to CLPT and SENS?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #999999 out of 445 companies for 10-Year Share Buyback Ratio. This places Sight Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 10-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Sight Sciences and its competitors. Sight Sciences's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.68, compared to a current price of $8.14 — trading 73.9% above its estimated fair value. The current 10-Year Share Buyback Ratio is 0.00. Sight Sciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $8.14 is trading 73.9% above its estimated GF Value™ of $4.68.
GuruFocus considers Sight Sciences to be Significantly Overvalued.
Key valuation signals for SGHT:
10-Year Share Buyback Ratio: 0.00
GF Value™: $4.68 vs. price of $8.14 (73.9% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
64GF Score
Get the complete analysis for SGHT
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
